

January 21, 2025

To The Manager, Listing Department <b>National Stock Exchange of India Limited</b> Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: <b>BLISSGVS</b>	To The General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: <b>506197</b>
---	--

Dear Sir/Madam,

**Subject: Intimation of Board Meeting to be held on Tuesday, January 28, 2025**

**Ref: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of Bliss GVS Pharma Limited ("**the Company**") is scheduled to be held on **Tuesday, January 28, 2025** at the registered office of the Company, inter-alia to consider, approve and take on record:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024; and
2. The proposal for issuance of Sweat Equity Shares pursuant to applicable provisions of the Companies Act, 2013, the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 and other applicable laws and regulations to Key Managerial Personnel and/or Senior Management Personnel and/or Employee(s) of the Company including determination of the issue price if any, subject to such regulatory and statutory approvals as may be required including approval of the shareholders of the Company.

Further, according to SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the trading window for dealing in shares of the Company was closed for all the Designated Persons and their immediate relatives of the Company from January 01, 2025 and shall remain closed till 48 hours after the announcement/declaration of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024 and Sweat Equity, as stated above, to the stock exchanges/information becomes generally available.

This intimation is also being uploaded to the Company's website at <http://www.blissgvs.com/>

Kindly acknowledge and take on record the same.

Thanking you,  
For **Bliss GVS Pharma Limited**

**Aditi Bhatt**  
Company Secretary

**Regd. Office :** 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : [info@blissgvs.com](mailto:info@blissgvs.com) • Website : [www.blissgvs.com](http://www.blissgvs.com) • CIN - L24230MH1984PLC034771

**Factory :** Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : [factory@blissgvs.com](mailto:factory@blissgvs.com)